Shitanshu Uppal
Low-Grade Serous Ovarian Carcinoma
Relevant Study Summaries
GOG 281: Trametinib in recurrent low-grade
MILO/ENGOT-ov11: Binimetinib in Recurrent Low-Grade Serous
In low-grade serous ovarian cancer, Binimetinib did not significantly improve PFS compared to standard of care chemotherapy.
Publications Update # 67
Human creativity and the need for connection, mini-tutorial on low-grade serous ovarian cancer, p53 on preoperative biopsy in endometrial cancer, final overall survival in SOC-1 trial
SOC-1: Secondary Cytoreduction in Platinum-Sensitive Relapsed Ovarian Cancer
Surgery did not improve overall survival, but it showed a benefit in certain analyses. This supports the potential efficacy of secondary cytoreduction in specialized centers and for selected patients.
Platinum-Resistant Recurrent Ovarian Cancer
AURELIA Trial: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer
Adding bevacizumab to chemotherapy significantly improves PFS and ORR in patients with platinum-resistant recurrent ovarian cancer.
Platinum Sensitive Recurrent Ovarian Cancer
OCEANS: Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
- Adding bevacizumab to gemcitabine and carboplatin significantly improves PFS but no difference in OS in platinum-sensitive recurrence
MITO 16B: Bevacizumab Maintenance with Platinum Doublets in Platinum-Sensitive Recurrence
Continuing bevacizumab beyond progression combined with chemotherapy significantly improves progression-free survival in patients with platinum-sensitive recurrent ovarian cancer compared to standard chemotherapy alone, but no OS benefit